ReNerve

ASX Announcement
29 July 2026

Quarterly Activities Report for the Period Ended 30 June 2026

Key Performance Highlights

- **Record quarterly sales of $211k, the Company's largest quarter to date**
- **Sales increased 50+% quarter-on-quarter with annual sales up 88%**
- **Customer cash receipts increased to $189k, reflecting continued commercial momentum**
- **Continued Market Expansion:** New distribution partnerships and regulatory progress across Malaysia, Hong Kong and Indonesia
- **Product Pipeline Progress:** NervAlign® Nerve Guide Matrix advanced to Stage 3 of its 4-stage development plan
- **Secures $5M funding facility:** ReNerve has secured an additional $5M in funding through Riverfort through its future R&D tax rebates

ReNerve Limited (ASX, "**ReNerve**" or "the **Company**"), an Australian biotechnology company developing innovative products for peripheral nerve injury ("PNI") repair, is pleased to present its Quarterly Report ("Report") for the period ended 30 June 2026 ("Q4 FY26", or the "Quarter"), as well as a financial and corporate update for the period.

During the Quarter, ReNerve delivered its strongest sales quarter to date, recording sales of $211k and cash receipts from customers of $189k. Full year sales reached $510,000, up 88% from the previous year, with the second half of the year having the strongest growth period. The result reflects continued growth across the Company's commercial product portfolio, particularly the Empliq range, and demonstrates the increasing contribution of multiple on-market products to ReNerve's revenue base. The cash at the end of the quarter was $1.488 million with ReNerve entering into a $5 million funding facility with Riverfort early in July to strengthen the company's cash position. The funding is underpinned by the Company's future R&D tax rebates.

Overall, the Quarter was productive, supported by record sales, increased cash receipts and continued expansion of the Company's commercial footprint. ReNerve progressed market access initiatives across key Asia-Pacific markets, including Malaysia, Hong Kong and Indonesia, and continued to advance hospital approvals to support broader adoption of its product portfolio.

The Company also achieved a major milestone in the NervAlign® Nerve Guide Matrix program, progressing a further stage toward FDA submission. The program entered Stage 3, which will generate product for manufacturing verification. The Nerve Guide Matrix program has already produced positive pre-clinical data in a nerve regeneration model, demonstrating its potential as a replacement option for injured nerves.

"This was our largest sales quarter to date and provides further evidence that our commercial strategy is gaining traction. With multiple products now on market and growing customer receipts, ReNerve is well placed to continue building momentum across its target markets," **said CEO Dr Julian Chick**.

Commercial Updates

Asia-Pacific commercial expansion

During the quarter, ReNerve advanced its Asia-Pacific commercialisation strategy through the appointment of distribution partners across two important regional markets, strengthening the pathway for adoption of its NervAlign product range outside the United States.

In Hong Kong, Macau and the Greater Bay Area, ReNerve executed an exclusive distribution agreement with Swedish Trading Company, a Hong Kong-headquartered medical device distributor with established relationships across hospitals and surgical networks in the region. The agreement covers an addressable population of approximately 88 million people and is structured for an initial three-year term, with performance milestones and renewal options. Swedish Trading Company will be responsible for importation, warehousing, marketing, sales and distribution of ReNerve products across the region, while ReNerve will provide clinical and technical support, training and regulatory liaison. The agreement follows ReNerve's expanded regulatory approval across the relevant jurisdictions, with the Company and Swedish Trading Company already shipping the first stocking orders into the Hong Kong region.

ReNerve also appointed UG Medical as its commercialisation partner for Malaysia, following regulatory clearance for NervAlign through Malaysia's Medical Device Authority earlier in the year. UG Medical is a Kuala Lumpur-based medical device distributor with an established network across Malaysian hospitals and healthcare facilities, and will support importation, regulatory management, warehousing, marketing, sales and distribution of the NervAlign product range. ReNerve will provide ongoing clinical and technical support, product training and regulatory liaison to assist UG Medical's commercialisation activities. The agreement provides ReNerve with access to a healthcare market of approximately 33 million people and comes as the Company prepares for the planned launch of its nerve conduit product in Malaysia later in 2026.

Subsequent to the end of the quarter, ReNerve also secured marketing approval for its NervAlign® Nerve Cuff in Indonesia, adding Southeast Asia's largest economy to its growing regional footprint alongside the United States, New Zealand, Hong Kong, Thailand and Malaysia. Indonesia represents one of ReNerve's largest single-country opportunities in the region, with a population of more than 280 million people and a significant clinical need for peripheral nerve repair solutions driven by trauma-related injuries and diabetes. The approval opens a new pathway for ReNerve to work with partners to bring the NervAlign Nerve Cuff to Indonesian clinicians and patients, further validating the Company's strategy of targeting high-potential Asia-Pacific healthcare markets.

Nerve Guide Matrix Enters Stage 3 of Commercial Development

In April, ReNerve advanced its NervAlign Nerve Guide Matrix into Stage 3 of the Company's four-stage scaled commercial production process, marking a key step toward FDA submission. Stage 3 represents the verification phase of development and is expected to generate product for the commencement of formal preclinical testing, production of associated packaging and manufacture of the final product, with completion targeted by the end of calendar 2026.

The Nerve Guide Matrix is being developed with a GMP production facility as a ready-to-use solution for the repair and replacement of injured or damaged nerves, with the aim of providing surgeons with an alternative to donor nerves, which can be limited by availability and the need for additional nerve harvesting. ReNerve is also maintaining engagement with the FDA throughout the commercial development process, with future testing to be undertaken in consideration of FDA feedback. Stage 4 will involve final production and testing of Nerve Guide Matrix batches ahead of formal marketing submission.

Empliq manufacturing capacity expanded to support growing demand

In June, ReNerve strengthened its manufacturing infrastructure for the Empliq™ product range through the appointment of J4 Biologics as a second approved manufacturing partner. J4 is a San Antonio, Texas-based human tissue processor specialising in the manufacture of amnion and dermal products, and was appointed following a qualification and evaluation process in which it met ReNerve's quality, compliance and production standards.

The partnership has been established in response to accelerating commercial traction for Empliq, including several recent new hospital approvals and increased market demand across the product's target customer segments. By adding a second qualified supplier alongside its existing manufacturer, ReNerve is seeking to increase total manufacturing output, improve product availability and support shorter lead times for existing and new customers.

The appointment also forms part of a broader dual-supplier strategy designed to improve supply chain resilience and reduce concentration risk as ReNerve scales its commercial operations. Under the agreement, J4 will manufacture Empliq inventory to ReNerve's specifications, providing additional production throughput and allowing inventory production to be scaled flexibly in line with demand. Initial production is expected to commence shortly following completion of onboarding and quality assurance processes.

The agreement has an initial three-year term, with automatic renewal for additional two-year periods unless terminated, and is non-exclusive. ReNerve is subject to minimum annual purchase commitments beginning at approximately 500 units in the first year and increasing in subsequent years, while pricing has been agreed for an initial 12-month period and may be varied thereafter on notice. The Company does not expect the agreement to have a material near-term impact on its financial performance, but views the additional manufacturing capacity as an important operational step to support the longer-term growth of Empliq and ensure it can meet rising customer demand as the commercial programme scales.

Financials

The Company continued to build its sales during the period, driven primarily by strong growth in Empliq sales and the increasing contribution from its broader product portfolio. Total sales for the quarter increased to $211k, up from $132k in the prior quarter, representing ReNerve's largest quarter to date. The Company's cumulative FY26 sales was A$510,000, up 88% from FY25. Cash receipts from customers for the quarter increased to $189k.

During the quarter, operating cash flows reflected continued investment in product development, manufacturing capability and commercial expansion. Research and development expenditure increased to $752k from $346k in the prior quarter, primarily reflecting the progression of the NervAlign® Nerve Guide Matrix program. Staff costs decreased to $363k from $511k in the prior quarter, while administration and corporate costs increased to $415k from $289k as the Company continued to refine its operating structure to support its next stage of growth.

Subsequent to the end of the quarter, the Company announced it had secured access to a funding facility of up to $5.0 million. The facility provides additional flexibility to support commercialisation, product expansion and market initiatives as ReNerve continues to scale its operations.

Quarterly investor update

During the quarter, ReNerve released a quarterly investor presentation and continued to provide updates to shareholders, investors and interested parties on the Company's commercial progress, product development activities and market expansion initiatives.

Corporate

During and following the quarter, ReNerve continued to strengthen its commercial and operational platform. As outlined above, the Company announced the appointment of J4 as a second approved manufacturing partner for the Empliq product range, supporting production scalability and supply continuity as market demand increases. ReNerve also announced further market expansion initiatives, including a Malaysian distribution partnership and marketing approval in Indonesia after quarter end.

As disclosed in Item 6.1 of the Appendix 4C, ReNerve made aggregate payments to related parties and their associates totalling $184k during the quarter. The payments consist of directors' fees, salary and associated payroll costs of non-executive and executive directors.

Comparison to IPO prospectus

Pursuant to Listing Rule 4.7C.2, the Company confirms that, in the fourth quarter since listing on the ASX, the Company's expenditure profile is largely in line with the use of funds set out in its Prospectus, as detailed in the table below. The Company remains focused on applying funds toward its strategic objectives and planned activities.

Use of Funds*	Expenditure allocated under prospectus (2-year period)	Actual expenditure to date 30 June 2026**
NervAlign Nerve Conduit Studies	$1,100,000	$622,502
Post market study for Nerve Cuff	$300,000	$293,644
Nerve Guide Matrix program	$3,000,000	$1,182,239
IPO costs	$900,000	$967,740
Working capital and operating expenses	$1,700,000	$3,933,875
Total Funds Allocated	**$7,000,000**	**$7,000,000**

** This table is a statement of current intentions of the Company. Actual use of funds may differ from the budgeted use of funds based on changes in clinical trials budgets or development expenses. The Board may alter the way funds are applied in the future.*

*** Actual expenditure to date 30 June 2026 per the above table reflects expenditures for the six quarters ended 30 June 2026, thus including expenditures incurred before the Company's ASX Listing on 26 November 2024.*

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

Follow ReNerve:

Website: www.renerve.com.au
LinkedIn: https://www.linkedin.com/company/renerve-ltd
InvestorHub: https://investors.renerve.com.au/

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comparison of Patient Pre & Post Surgery Pain Score



Standard of Care vs NervAlign®Nerve Cuff Protected Nerve Repairs

The comparison of pain scores between the two cohorts of patients

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs:

On market

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Empliq™ Deep Dermal tissue product --** A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Empliq™ Amniotic tissue product ranges --** Three amniotic tissue product ranges used to aid the healing of wounds.

In development

- **NervAlign® Nerve Conduit Range –** Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales and YTD FY2026 sales revenues showing further significant increases across its portfolio. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.[1]

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

[1] Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
ReNerve Limited	
ABN	**Quarter ended ("current quarter")**
23 614 848 216	30 June 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	189	376
1.2	Payments for		
	(a) research and development	(752)	(1,666)
	(b) product manufacturing and operating costs	(170)	(1,019)
	(c) advertising and marketing	(216)	(826)
	(d) leased assets	-	-
	(e) staff costs	(363)	(1,926)
	(f) administration and corporate costs	(415)	(1,334)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	23	117
1.5	Interest and other costs of finance paid	(5)	(11)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	517
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(1,709)**	**(5,772)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(3)	(85)
	(d) investments	-	-
	(e) intellectual property	(3)	(75)
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(6)**	**(160)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	3,200
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(29)	(291)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(49)	(81)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Principal payments of lease liabilities)	(24)	(79)
3.10	**Net cash from / (used in) financing activities**	**(102)**	**2,749**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	3,325	4,754
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,709)	(5,772)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(6)	(160)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(102)	2,749
4.5	Effect of movement in exchange rates on cash held	(20)	(83)
4.6	**Cash and cash equivalents at end of period**	**1,488**	**1,488**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	469	1,085
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (Term Deposits)	1,019	2,240
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,488**	**3,325**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	184
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities		
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	**Total financing facilities**		

7.5	**Unused financing facilities available at quarter end**	
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,709)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,488
8.3	Unused finance facilities available at quarter end (item 7.5)	
8.4	Total available funding (item 8.2 + item 8.3)	1,488
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	0.9

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: The Company expects operating cash outflows to remain broadly consistent with current levels as it continues to execute its commercialisation strategy. The June 2026 quarter included a number of significant research and development activities and product commercialisation initiatives, some of which were non-recurring in nature. The Company continues to actively manage expenditure while pursuing revenue growth through the expansion of its product portfolio, sales and distribution activities.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: As announced to the ASX on 9 July 2026, the Company secured a funding facility of up to A$5 million with RiverFort Global Opportunities PCC Ltd. The facility provides access to staged funding over a three-year period and is intended to support the Company's commercialisation strategy, working capital requirements and general corporate purposes. The Company believes the facility provides access to sufficient funding to support its near-term operational requirements.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: The Company expects to continue its operations and meet its business objectives based on its existing cash reserves, access to funding under the recently announced RiverFort funding facility, ongoing management of operating expenditure and continued execution of its commercialisation strategy and revenue growth initiatives.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 29 July 2026

Authorised by: By the Board of Directors of ReNerve Limited
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.